

Arun S Singh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3177605/publications.pdf>

Version: 2024-02-01

55
papers

1,783
citations

293460

24
h-index

312153

41
g-index

55
all docs

55
docs citations

55
times ranked

1832
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 84-94.	3.2	22
2	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. <i>Clinical Cancer Research</i> , 2022, 28, 298-307.	3.2	12
3	A phase 1 dose-escalation/expansion clinical trial of mocetinostat in combination with vinorelbine in adolescents and young adults with refractory and/or recurrent rhabdomyosarcoma: Interim results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11553-11553.	0.8	3
4	Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab. <i>Rare Tumors</i> , 2021, 13, 203636132110347.	0.3	4
5	Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies. <i>Current Treatment Options in Oncology</i> , 2021, 22, 9.	1.3	4
6	Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review. <i>Rheumatology International</i> , 2021, 41, 1357-1367.	1.5	2
7	A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11567-11567.	0.8	4
8	Recurrence and disease-specific survival after 10-year disease-free interval in patients with primary retroperitoneal liposarcoma: Implications for long-term surveillance.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11546-11546.	0.8	0
9	A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 4225-4232.	3.2	22
10	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	2.1	11
11	A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11017-11017.	0.8	15
12	Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11072-11072.	0.8	0
13	Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11020-11020.	0.8	1
14	Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	1.0	28
15	Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2018, 17, 801-809.	1.3	57
16	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018, 17, 627-633.	1.3	13
17	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	3.2	56
18	Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 967-972.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018, 17, 356-361.	1.3	40
20	Growth of doxorubicin-resistant undifferentiated spindle cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3537-3544.	1.2	30
21	Combining Tumor-Selective Bacterial Therapy with <i>Salmonella typhimurium</i> A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. <i>Chemotherapy</i> , 2018, 63, 278-283.	0.8	25
22	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	1.0	29
23	Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2018, 38, 5639-5644.	0.5	50
24	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting <i>Salmonella typhimurium</i> A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	1.0	18
25	Combination therapy of tumor-targeting <i>Salmonella typhimurium</i> A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	1.0	27
26	Tumor-targeting <i>Salmonella typhimurium</i> A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7827-7833.	1.2	6
27	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	7.1	5
28	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle cell sarcoma patient-derived orthotopic xenograft (PDOX): precision oncology nude mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6598-6603.	1.2	14
29	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	1.0	18
30	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	1.1	14
31	Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	1.4	11
32	A randomized phase 2 study of nivolumab monotherapy versus nivolumab combined with ipilimumab in patients with metastatic or unresectable gastrointestinal stromal tumor (GIST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 55-55.	0.8	9
33	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , 2018, 9, 7774-7781.	0.8	22
34	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018, 9, 11119-11125.	0.8	35
35	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 19263-19272.	0.8	22
36	Potential of immunotherapy for sarcoma. <i>Cancer</i> , 2017, 123, 1488-1489.	2.0	4

#	ARTICLE	IF	CITATIONS
37	High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2739-2743.	1.2	34
38	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017, 16, 1063-1069.	1.3	30
39	Intra-arterial administration of tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , 2017, 16, 1164-1170.	1.3	49
40	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	1.3	37
41	The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. <i>Cell Cycle</i> , 2017, 16, 1046-1052.	1.3	38
42	Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 35630-35638.	0.8	77
43	Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 75874-75880.	0.8	33
44	Toxicology and efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R compared to VNP 20009 in a syngeneic mouse tumor model in immunocompetent mice. <i>Oncotarget</i> , 2017, 8, 54616-54628.	0.8	16
45	A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 63353-63359.	0.8	24
46	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017, 8, 62111-62119.	0.8	48
47	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017, 8, 103129-103136.	0.8	38
48	Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines. <i>Anticancer Research</i> , 2017, 37, 4081-4084.	0.5	5
49	Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11048-11048.	0.8	2
50	Patient-reported Symptoms of Tenosynovial Giant Cell Tumors. <i>Clinical Therapeutics</i> , 2016, 38, 778-793.	1.1	79
51	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. <i>Oncotarget</i> , 2016, 7, 64300-64308.	0.8	44
52	Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i> -deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016, 7, 47556-47564.	0.8	91
53	Ewing Sarcoma in a Patient With Cowden Syndrome. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1310-1314.	2.3	5
54	Giant-cell tumor of bone: treatment options and role of denosumab. <i>Biologics: Targets and Therapy</i> , 2015, 9, 69.	3.0	49

#	ARTICLE	IF	CITATIONS
55	Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. New England Journal of Medicine, 2015, 373, 428-437.	13.9	438